Related Experiment Videos
Serum beta 2-microglobulin in chronic liver diseases
The Tohoku Journal of Experimental Medicine
|June 1, 1981
Summary
Serum beta 2-microglobulin levels are not useful for diagnosing chronic hepatitis or fatty liver. However, elevated levels were observed in liver cirrhosis and primary liver carcinoma patients.
Area of Science:
- Biochemistry
- Hepatology
- Clinical Diagnostics
Background:
- Serum beta 2-microglobulin (SBM) is a protein found on cell surfaces.
- Its levels can change in various diseases, including liver conditions.
Purpose of the Study:
- To evaluate the diagnostic utility of SBM in differentiating chronic liver diseases.
- To assess SBM levels in fatty liver, chronic hepatitis, liver cirrhosis, and primary liver carcinoma.
Main Methods:
- Serum samples were collected from 53 patients with various chronic liver diseases.
- SBM concentrations were measured using a standard laboratory assay.
Main Results:
- SBM showed no elevation in fatty liver due to obesity or alcoholism.
- Abnormal SBM levels were found in only 4% of chronic hepatitis patients.
- SBM was elevated in 29% of alcoholic liver cirrhosis, 41% of non-alcoholic liver cirrhosis, and 75% of primary liver carcinoma patients.
- Non-alcoholic liver cirrhosis showed higher average SBM than alcoholic liver cirrhosis.
- A correlation was observed between SBM and gamma-globulin in liver cirrhosis.
Conclusions:
- SBM determination is not useful for differentiating chronic hepatitis from fatty liver.
- SBM may serve as a potential biomarker for liver cirrhosis and primary liver carcinoma.
- Higher SBM levels in non-alcoholic liver cirrhosis warrant further investigation.